主动监测在局限性前列腺癌管理中的作用。
Role of active surveillance in the management of localized prostate cancer.
作者信息
Glass Allison S, Cooperberg Matthew R, Meng Maxwell V, Carroll Peter R
机构信息
Department of Urology, University of California-San Francisco, CA 94143-1695, USA.
出版信息
J Natl Cancer Inst Monogr. 2012 Dec;2012(45):202-6. doi: 10.1093/jncimonographs/lgs032.
Abstract
Active surveillance is an increasingly recognized treatment option for men with low-risk prostate cancer. Despite encouraging evidence for oncologic efficacy and reduction in morbidity, several barriers contribute to the underuse of this management strategy. Consistent selection criteria as well as identification and validation of triggers for subsequent intervention are essential. Incorporation of novel biomarkers as well as advanced imaging techniques may improve surveillance strategies by better defining eligibility as well as improving prompt detection of disease progression.
摘要
主动监测是一种越来越被认可的针对低风险前列腺癌男性的治疗选择。尽管有令人鼓舞的肿瘤学疗效证据以及发病率降低的证据，但仍有几个障碍导致这种管理策略未得到充分应用。一致的选择标准以及后续干预触发因素的识别和验证至关重要。纳入新型生物标志物以及先进的成像技术可能会通过更好地确定入选标准以及改善疾病进展的及时检测来改进监测策略。
相似文献
1
Role of active surveillance in the management of localized prostate cancer.
J Natl Cancer Inst Monogr. 2012 Dec;2012(45):202-6. doi: 10.1093/jncimonographs/lgs032.
2
An evidence review of active surveillance in men with localized prostate cancer.
Evid Rep Technol Assess (Full Rep). 2011 Dec(204):1-341.
3
National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.
Ann Intern Med. 2012 Apr 17;156(8):591-5. doi: 10.7326/0003-4819-156-8-201204170-00401. Epub 2012 Feb 20.
4
Active surveillance for prostate cancer: overview and update.
Curr Treat Options Oncol. 2013 Mar;14(1):97-108. doi: 10.1007/s11864-012-0221-5.
5
Prostate cancer: surgery versus observation for localized prostate cancer.
Nat Rev Urol. 2014 Jun;11(6):312-3. doi: 10.1038/nrurol.2014.109. Epub 2014 May 13.
6
Active surveillance in men with localized prostate cancer: a systematic review.
Ann Intern Med. 2012 Apr 17;156(8):582-90. doi: 10.7326/0003-4819-156-8-201204170-00397. Epub 2012 Feb 20.
7
Low-risk Prostate Cancer: Identification, Management, and Outcomes.
Eur Urol. 2017 Aug;72(2):238-249. doi: 10.1016/j.eururo.2017.03.009. Epub 2017 Mar 18.
8
Active Surveillance as Initial Management of Newly Diagnosed Prostate Cancer: Data from the PURC.
J Urol. 2019 May;201(5):929-936. doi: 10.1016/j.juro.2018.10.018.
9
Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer.
Eur Urol. 2015 Jun;67(6):993-1005. doi: 10.1016/j.eururo.2015.01.004. Epub 2015 Jan 21.
10
[Active surveillance is a useful strategy in the management of patients with low-risk prostate cancer].
Ugeskr Laeger. 2015 Apr 27;177(18):841-5.
引用本文的文献
1
Racial and Ethnic Differences in Prostate Cancer Survivors' Perceived Engagement in Treatment Decision-Making.
J Racial Ethn Health Disparities. 2018 Dec;5(6):1273-1283. doi: 10.1007/s40615-018-0475-0. Epub 2018 Mar 7.
2
Active surveillance for low-risk prostate cancer in Austria: the online registry of the Qualitätspartnerschaft Urologie (QuapU).
Wien Klin Wochenschr. 2017 Jun;129(11-12):375-379. doi: 10.1007/s00508-016-1149-8. Epub 2016 Dec 21.
3
Evolution of a CDC Public Health Research Agenda for Low-Risk Prostate Cancer.
Am J Prev Med. 2015 Dec;49(6 Suppl 5):S483-8. doi: 10.1016/j.amepre.2015.08.016.
4
Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.
J Urol. 2014 Mar;191(3):629-37. doi: 10.1016/j.juro.2013.09.029. Epub 2013 Sep 20.
本文引用的文献
1
The quantitative Gleason score improves prostate cancer risk assessment.
Cancer. 2012 Dec 15;118(24):6046-54. doi: 10.1002/cncr.27670. Epub 2012 Jun 6.
2
National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.
Ann Intern Med. 2012 Apr 17;156(8):591-5. doi: 10.7326/0003-4819-156-8-201204170-00401. Epub 2012 Feb 20.
3
Cancer statistics, 2012.
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
4
Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer.
BJU Int. 2012 May;109(9):1315-22. doi: 10.1111/j.1464-410X.2011.10612.x. Epub 2011 Sep 20.
5
The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study.
J Urol. 2011 Aug;186(2):465-9. doi: 10.1016/j.juro.2011.03.115. Epub 2011 Jun 15.
6
Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance.
J Clin Oncol. 2011 Jul 10;29(20):2795-800. doi: 10.1200/JCO.2010.33.0134. Epub 2011 May 31.
7
Tumour markers in prostate cancer III: biomarkers in urine.
Acta Oncol. 2011 Jun;50 Suppl 1:85-9. doi: 10.3109/0284186X.2010.524935.
8
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.
J Clin Oncol. 2011 Jun 1;29(16):2185-90. doi: 10.1200/JCO.2010.32.8112. Epub 2011 Apr 4.
9
The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer.
J Urol. 2011 May;185(5):1656-60. doi: 10.1016/j.juro.2010.12.042. Epub 2011 Mar 21.
10
Ki67 and BUBR1 may discriminate clinically insignificant prostate cancer in the PSA range <4 ng/ml.
Jpn J Clin Oncol. 2011 Apr;41(4):555-64. doi: 10.1093/jjco/hyq233. Epub 2011 Jan 12.
Zotero 插件